New radiation approach aims to tame tough pancreatic tumors

NCT ID NCT02780648

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a highly targeted form of radiation called stereotactic body radiation therapy (SBRT) in 36 patients with pancreatic cancer that could not be removed by surgery or had come back after other treatments. The main goal was to see how safe the treatment was by tracking serious side effects within three months. Researchers also looked at longer-term side effects, tumor control, survival, pain relief, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this could show that SBRT is a safe option for controlling pancreatic tumors that cannot be removed surgically, potentially improving local control and quality of life.
What could go wrong
This is a small, early-phase pilot study with only 36 participants and no comparison group. The results may not apply to all patients, and there are risks of serious gastrointestinal side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE AMPULLA OF VATER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Indiana University Health Hospital

    Indianapolis, Indiana, 46202, United States

  • Indiana University Health Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.